Drug Class Combination–Associated Acute Kidney Injury

Annals of Pharmacotherapy

Volumn 50, Issue 11, 2016, Pages 953-972

  Rivosecchi, Ryan M ^a   Kellum, John A ^b   Dasta, Joseph F ^c   Armahizer, Michael J ^d   Bolesta, Scott ^e   Buckley, Mitchell S ^f   Dzierba, Amy L ^g   Frazee, Erin N ^h   Johnson, Heather J ^b   Kim, Catherine ^a   Murugan, Raghavan ^b   Smithburger, Pamela L ^b   Wong, Adrian ⁱ   Kane Gill, Sandra L ^b  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^e WILKES UNIVERSITY   (United States)

^f BANNER HEALTH   (United States)

^g NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^h MAYO CLINIC   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

adverse drug reactions; kidney failure; nephrology; nephrotoxicity; renal failure

Indexed keywords

CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FENOFIBRATE; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; MACROLIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN PLUS TAZOBACTAM; POLYGELINE; SIMVASTATIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; BIBLIOGRAPHIC DATABASE; DISEASE COURSE; DRUG COMBINATION; DRUG SAFETY; HUMAN; INTENSIVE CARE; KIDNEY PERFUSION; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY;

ACUTE KIDNEY INJURY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84990225191     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028016657839     Document Type: Review

References (119)

1. Hoste EA, Bagshaw SM, Bellomo R. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411-1423. doi:10.1007/s00134-015-3934-7.
2. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16:3365-3370. doi:10.1681/ASN.2004090740.
3. Kane-Gill SL, Sileanu FE, Murugan R, Trietley GS, Handler SM, Kellum JA. Risk factors for acute kidney injury in older adults with critical illness: a retrospective cohort study. Am J Kidney Dis. 2015;65:860-869. doi:10.1053/j.ajkd.2014.10.018.
4. Cartin-Ceba R, Kashiouris M, Plataki M, Kor DJ, Gajic O, Casey ET. Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Crit Care Res Pract. 2012;2012:691013. doi:10.1155/2012/691013.
5. Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin. 2006;22:357-374, viii. doi:10.1016/j.ccc.2006.02.003.
6. Kohli HS, Bhaskaran MC, Muthukumar T. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant. 2000;15:212-217.
7. Nolin TD, Himmelfarb J. Mechanisms of drug-induced nephrotoxicity. Handb Exp Pharmacol. 2010;(196):111-130. doi:10.1007/978-3-642-00663-0_5.
8. Atkins D, Best D, Briss PA. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490. doi:10.1136/bmj.328.7454.1490.
9. Sany D, Refaat H, Elshahawy Y, Mohab A, Ezzat H. Frequency and risk factors of contrast-induced nephropathy after cardiac catheterization in type II diabetic patients: a study among Egyptian patients. Ren Fail. 2014;36:191-197. doi:10.3109/0886022X.2013.843400.
10. Akoglu H, Yilmaz R, Kirkpantur A, Arici M, Altun B, Turgan C. Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure. Ann Pharmacother. 2007;41:143-147. doi:10.1345/aph.1H251.
11. Buyukhatipoglu H, Sezen Y, Guntekin U, Kirhan I, Dag OF. Acute renal failure with the combined use of rosuvastatin and fenofibrate. Ren Fail. 2010;32:633-635. doi:10.3109/08860221003759452.
12. Al-Olah YH, Carr-Lope SM. Rhabdomyolysis secondary to the concomitant use of simvastatin and gemfibrozil. Saudi Pharmaceutical J. 2002;10:65-69.
13. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med. 1990;112:228-230.
14. Unal A, Torun E, Sipahioglu MH. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Intern Med. 2008;47:1017-1019.
15. Teutonico A, Libutti P, Lomonte C, Basile C. Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis. Nephrol Dial Transplant. 2010;3:273-275.
16. Scarfia RV, Clementi A, Granata A. Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine. Ren Fail. 2013;35:1056-1057. doi:10.3109/0886022X.2013.810540.
17. Kusus M, Stapleton DD, Lertora JJ, Simon EE, Dreisbach AW. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci. 2000;320:394-397.
18. Ellison NM, Servi RJ. Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep. 1985;69:342-343.
19. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet. 1986;1:1390.
20. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. Lancet. 1986;1:1390.
21. Avent CK, Krinsky D, Kirklin JK, Bourge RC, Figg WD. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. Am J Med. 1988;85:452-453.
22. Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporin A. J Antimicrob Chemother. 1988;21:679-680.
23. Nasir M, Rotellar C, Hand M, Kulczycki L, Alijani MR, Winchester JF. Interaction between ciclosporin and ciprofloxacin. Nephron. 1991;57:245-246.
24. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327:147-149. doi:10.1136/bmj.327.7407.147.
25. Lee HC, Pettinger WA. Diuretics potentiate the angiotensin converting-enzyme inhibitor-associated acute renal dysfunction. Clin Nephrol. 1992;38:236-237.
26. Hofer-Dueckelmann C, Prinz E, Beindl W. Adverse drug reactions (ADRs) associated with hospital admissions: elderly female patients are at highest risk. Int J Clin Pharmacol Ther. 2011;49:577-586.
27. Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc. 2008;100:444-446.
28. Roques S, Lytrivi M, Rusu D, Devriendt J, De Bels D. Rhabdomyolysis-induced acute renal failure due to itraconazole and simvastatin association. Drug Metabol Drug Interact. 2011;26:79-80. doi:10.1515/DMDI.2011.106.
29. Weibert RT, Keane WF. Carbenicillin-gentamicin interaction in acute renal failure. Am J Hosp Pharm. 1977;34:1137-1139.
30. Yver L. Nephrotoxicity of methicillin/aminoglycoside. Lancet. 1978;2:1314.
31. Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K. Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol. 2006;19:515-517.
32. Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C. Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD): possible role of clarithromycin administration. Clin Nephrol. 2001;55:181-182.
33. Liu GJ, Wang Y, Zeng YJ. The combined use of edaravone, diuretics, and nonsteroidal anti-inflammatory drugs caused acute kidney injury in an elderly patient with chronic kidney disease. CEN Case Rep. 2012;1:96-103.
34. Simpson IJ. Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine. N Z Med J. 1971;74:312-315.
35. Marusic S, Lisicic A, Horvatic I, Bacic-Vrca V, Bozina N. Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction. Int J Clin Pharm. 2012;34:825-827. doi:10.1007/s11096-012-9717-0.
36. Dopazo C, Bilbao I, Lazaro JL. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant Proc. 2009;41:1021-1024. doi:10.1016/j.transproceed.2009.02.019.
37. Lim AK, Ho L, Levidiotis V. Quinine-induced renal failure as a result of rhabdomyolysis, haemolytic uraemic syndrome and disseminated intravascular coagulation. Intern Med J. 2006;36:465-467. doi:10.1111/j.1445-5994.2006.01104.x.
38. Lucas RA, Weathersby BB, Rocco VK, Pepper JM, Butler KL. Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital. Pharmacotherapy. 2002;22:771-774.
39. Mogyorosi A, Bradley B, Showalter A, Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med. 1999;246:599-602.
40. Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can J Clin Pharmacol. 2003;10:172-174.
41. Ram R, Swarnalatha G, Ramesh V, Rao KN, Dakshinamurty KV. Rhabdomyolysis induced acute renal failure secondary to statins. Indian J Nephrol. 2013;23:211-213. doi:10.4103/0971-4065.111853.
42. Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40:33-36. doi:10.4997/JRCPE.2010.108.
43. Clark CJ, Hawley CM, Mudge DW. Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report. J Med Case Rep. 2010;4:276. doi:10.1186/1752-1947-4-276.
44. Marin-Casino M, Perez-Saez MJ, Crespo M, Echeverria D, Mir M, Pascual J. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. Transplantation. 2014;98:e33-e34. doi:10.1097/TP.0000000000000280.
45. Sheiner PA, Mor E, Chodoff L. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. Transplantation. 1994;57:1132-1133.
46. Patni H, Gitman M, Hazzan A, Jhaveri KD. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. Ren Fail. 2012;34:251-253. doi:10.3109/0886022X.2011.647210.
47. Olyaei AJ, deMattos AM, Norman DJ, Bennett WM. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy. 1998;18:1356-1359.
48. Gokel Y, Paydas S, Duru M. High-dose verapamil-trandolapril induced rhabdomyolysis and acute renal failure. Am J Emerg Med. 2000;18:738-739.
49. Kerbusch T, Mathot RA, Otten HM. Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report. Pharmacol Toxicol. 2002;90:243-245.
50. Matsumura M. Mannitol-induced toxicity in a diabetic patient receiving losartan. Am J Med. 2001;110:331.
51. Lehmann K, Ritz E. Angiotensin-converting enzyme inhibitors may cause renal dysfunction in patients on long-term lithium treatment. Am J Kidney Dis. 1995;25:82-87.
52. Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ. 2013;185:E475-E482. doi:10.1503/cmaj.121730.
53. Wood M, Sebel E, O’Sullivan WJ. Allopurinol and thiazides. Lancet. 1972;299:751. doi:10.1016/S0140-6736(72)90271-1.
54. Murphy MD, O’Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis. 2003;36:1082-1085. doi:10.1086/368313.
55. Baeza MT, Merino E, Boix V, Climent E. Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS. 2007;21:119-120. doi:10.1097/QAD.0b013e3280117f6f.
56. Aouinti I, Gaies E, Trabelsi S. Delayed elimination of methotrexate in a patient receiving ciprofloxacin. Therapie. 2013;68:175-177. doi:10.2515/therapie/2013031
57. Kanwar VS, Pearce J. Acute renal failure in a 17-year-old female with ALL receiving escalating intravenous methotrexate without leukovorin. Pediatr Blood Cancer. 2007;49:216; author reply 9. doi:10.1002/pbc.20940.
58. de Miguel D, Garcia-Suarez J, Martin Y, Gil-Fernandez JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant. 2008;23:3762-3766. doi:10.1093/ndt/gfn503.
59. Brodsky A, Aparici I, Argeri C, Goldenberg D. Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity. J Clin Pharmacol. 1989;29:821-823.
60. Mita AC, Sundaram S, Saratopoulos J. Cabazitaxel plus cisplatin coadministration and drug-interaction study in patients with advanced solid tumors [abstract e15116]. J Clin Oncol. 2012;30(15, suppl 1).
61. Salem PA, Jabboury KW, Khalil MF. Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy. Oncology. 1982;39:31-32.
62. Hong YA, Kim H, Jo K. Severe rhabdomyolysis associated with concurrent use of simvastatin and sirolimus after cisplatin-based chemotherapy in a kidney transplant recipient. Exp Clin Transplant. 2014;12:152-155.
63. Price G. Metformin lactic acidosis, acute renal failure and rofecoxib. Br J Anaesth. 2003;91:909-910.
64. Schechner V, Hershcovici T, Beigel Y. Rhabdomyolysis due to combined therapy with cerivastatin and diclofenac. J Pharm Technol. 2003;19:219-221.
65. Visweswaran P, Massin EK, Dubose TD, Jr. Mannitol-induced acute renal failure. J Am Soc Nephrol. 1997;8:1028-1033.
66. Stevens SL, Goldman MH. Cyclosporine toxicity associated with allopurinol. South Med J. 1992;85:1265-1266.
67. Morales JM, Munoz MA, Fernandez Zatarain G. Reversible acute renal failure caused by the combined use of foscarnet and cyclosporin in organ transplanted patients. Nephrol Dial Transplant. 1995;10:882-883.
68. Kiss D, Thiel G. Glucose-intolerance and prolonged renal-transplant insufficiency due to ketoconazole-cyclosporin A interaction. Clin Nephrol. 1990;33:207-208.
69. Garcia TM, da Costa JA, Costa RS, Ferraz AS. Acute tubular necrosis in kidney transplant patients treated with enalapril. Ren Fail. 1994;16:419-423.
70. Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A. Enhancement of cyclosporine A nephrotoxicity by diclofenac. Clin Nephrol. 1987;27:213-214.
71. Al-Niaimi F, Lyon CC. Acute kidney injury due to interaction of methyl-1-testosterone with ciclosporin metabolism in a patient with severe atopic dermatitis. Dermatol Ther (Heidelb). 2013;3:211-214. doi:10.1007/s13555-013-0038-6.
72. Bouquie R, Deslandes G, Renaud C, Dailly E, Haloun A, Jolliet P. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol. 2011;17:28-30. doi:10.1097/RHU.0b013e3182056042.
73. Lopez-Ruiz A, del Peso-Gilsanz C, Meoro-Aviles A. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci. 2010;32:559-561. doi:10.1007/s11096-010-9423-8.
74. Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med. 2007;20:411-416. doi:10.3122/jabfm.2007.04.060187.
75. Cabanillas F, Burgos RC, Rodriguez C, Baldizon C. Nephrotoxicity of combined cephalothin-gentamicin regimen. Arch Intern Med. 1975;135:850-852.
76. Drew JH, Watson A, Evans JH, Smyth AR. Antibiotics and acute renal failure in children with cystic fibrosis. Paed Perinatal Drug Ther. 2002;5:65-67.
77. Fillastre JP, Laumonier R, Humbert G. Acute renal failure associated with combined gentamicin and cephalothin therapy. Br Med J. 1973;2:396-397.
78. Tvedegaard E. Letter: interaction between gentamicin and cephalothin as cause of acute renal failure. Lancet. 1976;2:581.
79. Seelig CB, Maloley PA, Campbell JR. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. South Med J. 1990;83:1144-1148.
80. Moffett BS, Cabrera A. Ketorolac-associated renal morbidity: risk factors in cardiac surgical infants. Cardiol Young. 2013;23:752-754. doi:10.1017/S1047951112001680.
81. Allon M, Pasque CB, Rodriguez M. Interaction of captopril and ibuprofen on glomerular and tubular function in humans. Am J Physiol. 1990;259(2, pt 2):F233-F238.
82. Sorli L, Luque S, Grau S. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380. doi:10.1186/1471-2334-13-380.
83. Rocco M, Montini L, Alessandri E. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care. 2013;17:R174. doi:10.1186/cc12853.
84. Totapally BR, Machado J, Lee H, Paredes A, Raszynski A. Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013;33:598-602. doi:10.1002/phar.1259.
85. Carreno JJ, Jaworski A, Kenney RM, Davis SL. Comparative incidence of nephrotoxicity by age group among adult patients receiving vancomycin. Infect Dis Ther. 2013;2:201-208. doi:10.1007/s40121-013-0022-6.
86. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M. Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction. Clin Nephrol. 2009;71:567-570.
87. Bickel M, Khaykin P, Stephan C. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med. 2013;14:633-638. doi:10.1111/hiv.12072.
88. Aamdal S. Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs? Ann Oncol. 1992;3:774.
89. Arora P, Kher V, Kohli HS, Sharma RK, Gupta A, Jha R. Acute renal failure in the elderly: experience from a single centre in India. Nephrol Dial Transplant. 1993;8:827-830.
90. Butkus DE, de Torrente A, Terman DS. Renal failure following gentamicin in combination with clindamycin. Nephron. 1976;17:307-313.
91. Deray G, Khayat D, Cacoub P. The effects of diltiazem on methotrexate-induced nephrotoxicity. Eur J Clin Pharmacol. 1989;37:337-340.
92. Christensen ML, Stewart CF, Crom WR. Evaluation of aminoglycoside disposition in patients previously treated with cisplatin. Ther Drug Monit. 1989;11:631-636.
93. Cao YL, Tian ZG, Wang F. Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced actue hepato-nephrotoxicity among Chinese patients. World J Gastroenterol. 2014;20:13956-13965. doi:10.3748/wjg.v20.i38.13956.
94. Nielson DV, Fedosova M, Hjortdal V, Jakobsen CJ. Is single-dose prophylactic gentamicin associated with acute kidney injury in patients undergoing cardiac surgery? A matched-pair analysis. J Thorac Cardiovasc Surg. 2014;148:1634-1639. doi:10.1016/j.jtcvs.2014.05.090.
95. Mathews A, Bailie GR. Acute renal failure and hyperkalemia associated with triamterene and indomethacin. Vet Hum Toxicol. 1986;28:224-225.
96. Weinberg MS, Quigg RJ, Salant DJ, Bernard DB. Anuric renal failure precipitated by indomethacin and triamterene. Nephron. 1985;40:216-218.
97. Lee BS, Byun SY, Chung ML. Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. Neonatology. 2010;98:191-199. doi:10.1159/000289206.
98. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med. 1982;96:317-320.
99. Hartmann D, Kleinbloesem CH, Lucker PW, Vetter G. Study on the possible interaction between tenoxicam and furosemide. Arzneimittelforschung. 1987;37:1072-1076.
100. Steinhauslin F, Munafo A, Buclin T, Macciocchi A, Biollaz J. Renal effects of nimesulide in furosemide-treated subjects. Drugs. 1993;46(suppl 1):257-262.
101. Audia P, Feinfeld DA, Dubrow A, Winchester JF. Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction. Clin Toxicol (Phila). 2008;46:164-166. doi:10.1080/15563650701355314.
102. Fournier JP, Sommet A, Durrieu G. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database. Fundam Clin Pharmacol. 2014;28:230-235. doi:10.1111/fcp.12014.
103. Adhiyaman V, Asghar M, Oke A, White AD, Shah IU. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med. 2001;94:512-514.
104. Fournier JP, Lapeyre-Mestre M, Sommet A, Dupouy J, Poutrain JC, Montastruc JL. Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study. PLoS One. 2012;7:e34187. doi:10.1371/journal.pone.0034187.
105. Loboz KK, Shenfield GM. Drug combinations and impaired renal function: the “triple whammy.” Br J Clin Pharmacol. 2005;59:239-243. doi:10.1111/j.0306-5251.2004.2188.x.
106. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. doi:10.1136/bmj.e8525.
107. Thomas MC. Diuretics, ACE inhibitors and NSAIDs: the triple whammy. Med J Aust. 2000;172:184-185.
108. Patel AM, Shariff S, Bailey DG. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158:869-876. doi:10.7326/0003-4819-158-12-201306180-00004.
109. Alreja G, Inayatullah S, Goel S, Braden G. Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin. J Cardiovasc Dis Res. 2012;3:319-322. doi:10.4103/0975-3583.102720.
110. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J. 1998;91:202-205.
111. Gandhi S, Fleet JL, Bailey DG. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310:2544-2553. doi:10.1001/jama.2013.282426.
112. Rossignol P, Cleland JG, Bhandari S. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation. 2012;125:271-279. doi:10.1161/CIRCULATIONAHA.111.028282.
113. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34:670-676. doi:10.1002/phar.1442.
114. Wang YC, Hsieh TC, Chou CL, Wu JL, Fant TC. Risks of adverse events following coprescription of statins and calcium channel blockers: a nationwide population-based study. Medicine (Baltimore). 2016;95:e2487. doi:10.1097/MD.0000000000002487.
115. Schneider M, Valentine S, Clarke GM, Newman MA, Peacock J. Acute renal failure in cardiac surgical patients, potentiated by gentamicin and calcium. Anaesth Intensive Care. 1996;24:647-650.
116. Young EW, Humes HD. Calcium and acute renal failure. Miner Electrolyte Metab. 1991;17:106-111.
117. Chao CT, Tsai HB, Wu CY. Cumulative cardiovascular polypharmacy is associated with the risk of acute kidney injury in elderly patients. Medicine (Baltimore). 2015;94:e1251. doi:10.1097/MD.0000000000001251.
118. Goldstein SL, Kirkendall E, Nguyen H. Electronic health record identification of nephrotoxin exposure and associated acute kidney injury. Pediatrics. 2013;132:e756-e767. doi:10.1542/peds.2013-0794.
119. Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med. 2002;112:505.